DaVita stock advances 2.07% and outperforms competitors
Updated
Updated · MarketWatch · Apr 30
DaVita stock advances 2.07% and outperforms competitors
6 articles · Updated · MarketWatch · Apr 30
Shares closed at $155.14 on Thursday, marking a third straight gain as the S&P 500 rose 1.02% and the Dow added 1.62%.
DaVita finished 2.68% below its 52-week high of $159.42 reached on 2 March.
Among peers, UnitedHealth slipped 0.07%, while Icon rose 1.86% and Quest Diagnostics gained 2.58%; DaVita trading volume of 741,896 was below its 50-day average.
After a key legal win, how will DaVita navigate growing federal antitrust scrutiny over its market dominance?
As competitors launch AI patient tools, is DaVita's home-care strategy enough to innovate the patient experience?